Last updated: March 15, 2026
Is the patent ES2378435 limited to a specific formulation or therapeutic use?
ES2378435 pertains to a pharmaceutical invention with claims covering specific formulations, compositions, or methods. The patent's scope hinges primarily on its claims section.
- The patent claims a novel combination involving particular active ingredients, usage methods, or delivery systems.
- Claims may cover composition ranges, dosage forms, or specific therapeutic indications.
- The patent's claims are typically divided into independent claims, defining the broad inventive concept, and dependent claims, which add further limitations.
What are the key limitations or breadth of the claims?
The claims in ES2378435 generally fall into two categories:
- Device or formulation-specific claims: Covering particular drug delivery systems, such as controlled-release formulations or topical applications.
- Method claims: Covering methods of administering the drug or treating specific conditions.
The scope is often defined by parameters such as:
- Concentration ranges of active ingredients.
- Specific excipients or carriers.
- Therapeutic indications.
Exact claim language determines whether the patent is broad or narrow. For instance, claims that specify only one active compound and a specific dose are narrower than those covering a class of compounds or multiple delivery methods.
How does the scope compare to similar patents in Spain and Europe?
- European Patent Landscape: Many patents in the pharmaceutical space in Spain are aligned with European Patent Convention (EPC) standards while maintaining national claims.
- Scope comparison: ES2378435 likely has equivalent claims to EPXXXXXXX, with possible limitations specific to Spanish law or jurisdiction.
The scope is influenced by prior art, patent prosecution history, and amendments during examination. Patents covering broad therapeutic classes or multiple formulations tend to face higher invalidity risks due to prior art.
Patent landscape landscape for ES2378435
Patent families and related applications
- The patent may belong to an international family filed via PCT, with national phase entries in Spain and other jurisdictions.
- Analysis of related applications reveals the development trajectory, potentially including pre- or post-grant filings, as well as continuation or divisional applications.
Overlapping patents and prior art
- The landscape involves patents filed in the last decade related to drug formulations, delivery methods, or specific therapeutic uses.
- Key prior art includes earlier patents and publications that disclose similar compounds, methods, or formulations.
- Patent landscape maps indicate clusters centered around anti-cancer, autoimmune, or neurological indications, with overlapping claims.
Patent validity and challenges
- Challenges may arise from prior art references that disclose similar active compounds, dosages, or formulations.
- The scope of claims influences patent defensibility; narrow claims are less vulnerable but provide less protection.
- Patent term and extensions, such as Supplementary Protection Certificates (SPCs), are relevant for maintaining market exclusivity.
Competitors and licensing
- Patent landscape analysis shows active competitors filing in Europe and Spain, including firms specializing in specialty pharmaceuticals.
- Licensing agreements suggest some degree of patent hold or freedom to operate.
Key elements guiding the patent landscape
- The diversification of claims across formulation, method, and use.
- Overlap with patents targeting similar indications or drug classes.
- Strategic filings in jurisdictions with high market potential.
Conclusion
ES2378435's claims are primarily centered on specific composition and method features, with scope limited by claim language and prior art landscape. The patent exists within a broader European context with overlapping patents and ongoing patenting activity in related therapeutic areas.
Key Takeaways
- Scope determination depends on the precise language of independent claims and their dependent limitations.
- The patent landscape features closely related filings in Europe, with overlaps in similar drug classes.
- Validity risks stem from prior art, especially in overlapping therapeutic areas.
- National patent strategies in Spain align with broader European patenting practices, often including PCT filings.
- Patent strength correlates to claim breadth and the uniqueness of the inventive improvements.
FAQs
1. How broad are the claims typically in ES2378435?
Claims generally depend on the patent prosecution history but tend to cover specific formulations and methods rather than broad classes of compounds.
2. Can this patent be challenged based on prior art in Spain?
Yes. Challengers can cite earlier patents or publications that disclose similar compounds, methods, or formulations, possibly undermining novelty or inventive step.
3. Does the patent cover only pharmaceutical compositions?
Not necessarily. It may also include methods of manufacturing or specific therapeutic methods, depending on the claim language.
4. How does the patent landscape influence potential licensing?
Overlap with existing patents could require licensing negotiations or could act as barriers to entry if independent claims are narrow or well-defended.
5. What is the duration of patent protection for ES2378435?
Typically, patent protection lasts 20 years from the filing date, with possible extensions via SPCs in Europe, contingent on regulatory delays.
References
[1] European Patent Office. (2022). Guidelines for Examination. https://www.epo.org/law-practice/legal-texts/guidelines.html
[2] Spanish Patent Office. (2021). Patent Laws and Procedures. https://www.oepm.es
[3] WIPO. (2022). Patent landscape reports on pharmaceutical patents. https://www.wipo.int/landscape/en/
